MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
Teleflex Incorporated Income Statement 2011-2026 | TFX
Annual Income Statement Teleflex Incorporated
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
6.21 B | 11.2 B | 11 B | 15.7 B | 18.4 B | 17.6 B | 12.5 B | 12.7 B | 7.17 B | 5.64 B | 4.53 B | 3.88 B | 3.07 B | 2.47 B |
Shares |
46.8 M | 47 M | 46.9 M | 46.8 M | 46.5 M | 46.2 M | 45.7 M | 45 M | 43.3 M | 41.6 M | 41.4 M | 41.1 M | 40.9 M | 40.5 M |
Historical Prices |
133 | 238 | 234 | 336 | 397 | 333 | 286 | 246 | 187 | 138 | 117 | 96.4 | 74.4 | 54 |
Net Income |
69.7 M | 356 M | 363 M | 485 M | 335 M | 461 M | 201 M | 153 M | 237 M | 245 M | 188 M | 151 M | -190 M | 323 M |
Revenue |
3.05 B | 2.97 B | 2.79 B | 2.81 B | 2.54 B | 2.6 B | 2.45 B | 2.15 B | 1.87 B | 1.81 B | 1.84 B | 1.7 B | 1.55 B | 1.53 B |
Cost of Revenue |
1.34 B | 1.33 B | 1.26 B | 1.26 B | 1.21 B | 1.19 B | 1.15 B | 975 M | 872 M | - | - | - | - | - |
Gross Profit |
1.7 B | 1.65 B | 1.53 B | 1.55 B | 1.32 B | 1.49 B | 1.38 B | 1.17 B | 996 M | 944 M | 942 M | 839 M | 748 M | 719 M |
Operating Income |
151 M | 506 M | 500 M | 628 M | 423 M | 427 M | 322 M | 372 M | 319 M | 316 M | 285 M | 233 M | -97.4 M | 230 M |
Interest Expense |
- | - | - | 57 M | 66.5 M | 80.3 M | 103 M | 82.5 M | 54.9 M | 61.3 M | 65.5 M | 56.9 M | 69.6 M | 70.3 M |
EBITDA |
426 M | 748 M | 730 M | 865 M | 650 M | 657 M | 610 M | 542 M | 492 M | 432 M | 414 M | 365 M | 318 M | 326 M |
Operating Expenses |
- | - | - | - | - | 1.05 B | 985 M | 785 M | 622 M | 621 M | 640 M | 567 M | 511 M | 479 M |
General and Administrative Expenses |
995 M | 930 M | 864 M | 860 M | 744 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Income Statement Teleflex Incorporated
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
44.2 M | 44.3 M | 45.8 M | 46.7 M | 47.2 M | 47.1 M | 47 M | 47 M | 46.9 M | - | 46.9 M | 46.9 M | 46.9 M | - | 46.8 M | 46.7 M | 46.7 M | - | 46.5 M | 46.4 M | 46.4 M | - | 46.2 M | 46.2 M | 46 M | - | 45.9 M | 45.6 M | 45.3 M | - | 45 M | 45 M | 44.9 M | - | 44 M | 43.5 M | 41.6 M | - | 41.6 M | 41.6 M | 41.5 M | - | 41.4 M | 41.4 M | 41.3 M | - | 41.1 M | 41.1 M | 41 M | - | 40.9 M | 40.8 M | 40.8 M | - | 40.7 M | 40.5 M | 40.1 M |
Net Income |
-409 M | 123 M | 95 M | 111 M | 80 M | 15.3 M | 137 M | 111 M | 76.7 M | - | 102 M | 106 M | 77.1 M | - | 199 M | 83.2 M | 74.9 M | 76.1 M | 117 M | 11.5 M | 131 M | 108 M | 229 M | 83.4 M | 40.9 M | 90.6 M | 56.5 M | -2.5 M | 56.2 M | -42.7 M | 77 M | 78 M | 40.2 M | 61.1 M | 66.3 M | 59.3 M | 50.7 M | 101 M | 60.8 M | 44.6 M | 38.4 M | 50.6 M | 54.8 M | 47.3 M | 35 M | 34.8 M | 46.6 M | 42.4 M | 27 M | 29.3 M | 21.7 M | 42.6 M | -284 M | 168 M | 43.7 M | 34.1 M | 77.8 M |
Revenue |
913 M | 781 M | 701 M | 764 M | 750 M | 738 M | 746 M | 743 M | 711 M | - | 687 M | 705 M | 642 M | - | 700 M | 713 M | 634 M | 711 M | 628 M | 567 M | 631 M | 681 M | 648 M | 653 M | 614 M | 642 M | 610 M | 610 M | 587 M | 595 M | 535 M | 529 M | 488 M | 514 M | 456 M | 474 M | 425 M | 485 M | 444 M | 452 M | 429 M | 476 M | 457 M | 468 M | 439 M | 451 M | 414 M | 420 M | 412 M | 419 M | 368 M | 383 M | 381 M | 403 M | 363 M | 381 M | 354 M |
Cost of Revenue |
461 M | 350 M | 311 M | 334 M | 333 M | 322 M | 330 M | 335 M | 320 M | - | 313 M | 316 M | 295 M | - | 312 M | 316 M | 289 M | - | 299 M | 289 M | 297 M | - | 293 M | 300 M | 290 M | - | 267 M | 265 M | 256 M | - | 239 M | 238 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
452 M | 431 M | 389 M | 430 M | 416 M | 416 M | 416 M | 408 M | 391 M | - | 374 M | 389 M | 346 M | - | 388 M | 398 M | 345 M | 384 M | 329 M | 278 M | 334 M | 378 M | 355 M | 352 M | 324 M | 366 M | 343 M | 345 M | 331 M | 331 M | 295 M | 290 M | 256 M | 273 M | 242 M | 256 M | 225 M | 260 M | 228 M | 233 M | 223 M | 241 M | 236 M | 244 M | 221 M | 225 M | 204 M | 209 M | 201 M | 199 M | 181 M | 184 M | 184 M | 190 M | 176 M | 181 M | 162 M |
Operating Income |
-409 M | 155 M | 126 M | 149 M | 117 M | -4.79 M | 165 M | 144 M | 115 M | - | 132 M | 135 M | 104 M | - | 241 M | 129 M | 103 M | 95.1 M | 132 M | 38.8 M | 157 M | 127 M | 118 M | 107 M | 75.2 M | 119 M | 82.1 M | 33.5 M | 86.8 M | 90.9 M | 110 M | 110 M | 60.8 M | 67 M | 86.5 M | 98.4 M | 67.5 M | 96.7 M | 76.6 M | 77 M | 65.6 M | 69.2 M | 81.9 M | 74.8 M | 59 M | 54.1 M | 66 M | 63.8 M | 49.4 M | 58.4 M | 49.8 M | 64.7 M | -270 M | 63.1 M | 61.9 M | 55.9 M | 48.7 M |
Interest Expense |
- | - | - | - | 21.2 M | 22.7 M | 23.2 M | 17.8 M | 18.3 M | - | 13.4 M | 11.4 M | 10.4 M | - | 12 M | 16.2 M | 16.8 M | - | 16.7 M | 15.7 M | 15.4 M | - | 19.5 M | 20.8 M | 22.7 M | - | 27.2 M | 26.6 M | 25.9 M | - | 21.3 M | 19.9 M | 17.7 M | - | 12.9 M | 11.9 M | 13.8 M | - | 14.3 M | 16.2 M | 17.2 M | - | 17.2 M | 16.1 M | 15.4 M | - | 13.9 M | 14.4 M | 14.2 M | - | 18.5 M | 18.2 M | 18.2 M | - | 19.2 M | 15.8 M | 16.1 M |
EBITDA |
-331 M | 221 M | 193 M | 218 M | 185 M | 61.3 M | - | - | 133 M | - | 182 M | 135 M | 121 M | - | 295 M | 129 M | 121 M | 95.1 M | 183 M | 73.3 M | 174 M | 127 M | 165 M | 139 M | 90.9 M | 119 M | 127 M | 63 M | 102 M | 90.9 M | 153 M | 138 M | 75 M | 67 M | 127 M | 125 M | 80.1 M | 96.7 M | 108 M | 108 M | 95.5 M | 69.2 M | 114 M | 107 M | 90.4 M | 54.1 M | 93.1 M | 89.4 M | 75.7 M | 58.4 M | 73.6 M | 87.5 M | -248 M | 63.1 M | 86.1 M | 80.3 M | 59 M |
General and Administrative Expenses |
282 M | 215 M | 223 M | 247 M | 251 M | 243 M | 213 M | 223 M | 233 M | - | 210 M | 217 M | 204 M | - | 205 M | 224 M | 203 M | - | 172 M | 191 M | 148 M | - | 209 M | 216 M | 207 M | - | 215 M | 230 M | 215 M | - | 164 M | 159 M | 164 M | - | 140 M | 143 M | 136 M | - | 139 M | 142 M | 140 M | - | 138 M | 147 M | 140 M | - | 115 M | 116 M | 127 M | - | 115 M | 106 M | 112 M | - | 102 M | 110 M | 103 M |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Teleflex Incorporated (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Medical instruments industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Atrion Corporation
ATRI
|
- | - | $ 810 M |  USA |
 |
Baxter International
BAX
|
$ 19.73 | 0.61 % | $ 10.1 B | USA |
 |
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | USA |
 |
Repro Med Systems
KRMD
|
$ 5.45 | -1.27 % | $ 249 M | USA |
 |
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | USA |
 |
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | USA |
 |
Masimo Corporation
MASI
|
$ 136.25 | -1.03 % | $ 7.26 B | USA |
 |
Merit Medical Systems
MMSI
|
$ 80.24 | -0.32 % | $ 4.67 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | USA |
 |
Ekso Bionics Holdings
EKSO
|
$ 8.39 | -1.29 % | $ 169 M | USA |
 |
Alcon
ALC
|
$ 81.15 | 0.91 % | $ 40.4 B |  Schweiz |
 |
AtriCure
ATRC
|
$ 36.95 | -2.17 % | $ 1.74 B | USA |
 |
Haemonetics Corporation
HAE
|
$ 65.96 | -0.15 % | $ 3.32 B | USA |
 |
electroCore
ECOR
|
$ 7.1 | -2.07 % | $ 39.2 K | USA |
 |
STERIS plc
STE
|
$ 261.64 | 0.3 % | $ 25.8 B | USA |
 |
AngioDynamics
ANGO
|
$ 9.98 | -0.3 % | $ 408 M | USA |
 |
ICU Medical
ICUI
|
$ 150.03 | 0.5 % | $ 3.66 B | USA |
 |
InfuSystem Holdings
INFU
|
$ 8.05 | -0.74 % | $ 166 M | USA |
 |
The Cooper Companies
COO
|
$ 80.37 | -0.14 % | $ 16 B | USA |
 |
Harvard Bioscience
HBIO
|
$ 0.54 | -6.29 % | $ 22.9 M | USA |
 |
Glaukos Corporation
GKOS
|
$ 119.07 | -3.93 % | $ 5.77 B | USA |
 |
Isoray
ISR
|
- | 0.03 % | $ 108 M | USA |
 |
Utah Medical Products
UTMD
|
$ 61.65 | 1.33 % | $ 224 M | USA |
 |
iRhythm Technologies
IRTC
|
$ 148.99 | -1.88 % | $ 4.65 B | USA |
 |
LeMaitre Vascular
LMAT
|
$ 83.86 | -1.41 % | $ 1.88 B | USA |
 |
Intuitive Surgical
ISRG
|
$ 507.55 | -2.78 % | $ 180 B | USA |
 |
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | USA |
 |
Microbot Medical
MBOT
|
$ 1.86 | -2.11 % | $ 19 M |  Israel |
 |
Nephros
NEPH
|
$ 4.39 | -2.66 % | $ 45.6 M | USA |
 |
Milestone Scientific
MLSS
|
$ 0.3 | 2.95 % | $ 23.9 M | USA |
 |
Envista Holdings Corporation
NVST
|
$ 23.39 | -2.87 % | $ 4.03 B | USA |
 |
OraSure Technologies
OSUR
|
$ 2.79 | 3.33 % | $ 208 M | USA |
 |
Pro-Dex
PDEX
|
$ 39.41 | -0.04 % | $ 130 M | USA |
 |
Predictive Oncology
POAI
|
- | - | $ 31.1 M | USA |
 |
Pulse Biosciences
PLSE
|
$ 13.62 | 0.52 % | $ 654 M | USA |
 |
Becton, Dickinson and Company
BDX
|
$ 201.09 | -0.41 % | $ 57.8 B | USA |
 |
Repligen Corporation
RGEN
|
$ 156.37 | -2.3 % | $ 8.71 M | USA |
 |
ResMed
RMD
|
$ 257.61 | -0.04 % | $ 37.6 B | USA |
 |
BioLife Solutions
BLFS
|
$ 22.58 | -1.57 % | $ 1.04 B | USA |
 |
Stereotaxis
STXS
|
$ 2.33 | -6.43 % | $ 188 M | USA |
 |
Retractable Technologies
RVP
|
$ 0.71 | 0.76 % | $ 21.3 M | USA |
 |
STAAR Surgical Company
STAA
|
$ 18.94 | -1.1 % | $ 930 M | USA |
 |
West Pharmaceutical Services
WST
|
$ 232.65 | -1.37 % | $ 17 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
$ 12.27 | -0.32 % | $ 2.49 B | USA |